Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio

Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio
Aerpio Pharmaceuticals announced a licensing agreement with Gossamer Bio to develop and commercialize Aerpio's investigative therapy AKB-4924 as a treatment for inflammatory bowel disease (IBD). AKB-4924 (to be changed to GB004) is a hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer. It works by blocking the prolyl-hydroxylase (PHD) enzymes, helping to stabilize HIF-1 alpha — a master regulator of the cellular response to hypoxia, a condition that happens when oxygen demand exceeds supply. Other HIF stabilizers in clinical development are not specific for HIF-1 alpha and stimulate other pathways, such as the production of red blood cells (a process called erythropoiesis). Studies have shown that inhibiting hydroxylase is protective in a mouse model of colitis, with later research suggesting that the protective effects of inhibiting PHDs were mediated through the protection of the intestinal barrier. HIF was shown to promote the production of several factors and the regulation of intestinal mucosal immune responses, contributing to the protective immune environment of the intestinal mucosa. In preclinical models of IBD, AKB-4924 was shown to improve intestinal inflammation and help restore intestinal barrier function. The treatment candidate is being developed as a once-daily, oral treatment for IBD. In 2017, Aerpio completed its first human trial, a Phase 1 study (
Subscribe or to access all post and page content.